The U.S. Food and Drug Administration has granted orphan drug status to cabozantinib for the treatment of hepatocellular carcinoma, the most common type of liver cancer.
Liver cancer
Scientists have long believed that liver cancer cells needed fat molecules to survive, and that by blocking fat production, the cancer would starve. But a new Australian…
Focused ultrasound appears to be able to selectively destroy liver tumors, new research from an EU project shows. Preliminary results of this new method, developed…
Combining the chemotherapy agent Sutent (sunitinib) and immunotherapy may be a promising strategy to fight hepatocellular carcinoma, the most common type of liver cancer, according…
News
Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or…
Recent Posts
- Biliary atresia treatment AX-0810 faring well in early testing
- Clinical trial results support bepirovirsen for hepatitis B
- Vitamin D may help protect against liver damage in those with PBC: Study
- Think smoking only affects your lungs? Your liver would like a word.
- Low vitamin D in early pregnancy tied to ICP risk, if fetus is a girl